Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

By C. Boutros, A. Tarhini, É. Routier, O. Lambotte, F. Ladurie, F. Carbonnel, Hassane Izzeddine, A. Marabelle, S. Champiat, A. Berdelou and 7 more. Nature Reviews Clinical Oncology, 2016

977 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ed79c0fd1fbe03aa93005a6320e5a086ff1c5b22

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Robert
2. R. Sherry

In Oncology

1. C. Robert
2. J. Haanen
3. J. Larkin
4. K. Kerr
5. S. Peters
6. F. Carbonnel
7. M. Lacouture
8. R. Sherry

Citations in the corpus

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “However, grade 3 or 4 rashes are rare, with an incidence of< 3% with monotherapy ipilimumab or anti-PD-1 and< 5% with the combination [2, 22].”
• EASL Clinical Practice Guidelines: Drug-induced liver injury. (2019, background): “Treatment emergent hepatotoxicity, although less common than other irAEs associated with the use of ICIs, has been detected in clinical trials powered for efficacy,(182) with ipilimumab leading to early treatment-related discontinuation in up to 11% of patients in clinical trials, while the combinat”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Most reports document isolated cases of interstitial nephritis with specific agents and regimens, such as anti-PD-1 monotherapy, and combination anti-CTLA-4/PD-1 treatment, in melanoma [91, 92].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “However, grade 3 or 4 rashes are rare, with an incidence of< 3% with monotherapy ipilimumab or anti-PD-1 and< 5% with the combination [2, 22].”